Table 2.
Topics related to the meningococcal B vaccine discussed in the videos
| Topic | Discussed, n (%) |
Not discussed, n (%) |
|---|---|---|
| Alert that a disease may be contracted that is preventable with immunization Benefits of the vaccine Recommendation in cases of epidemic outbreak |
62 (80.5)53 (68.8)22 (28.6) | 15 (19.5)24 (31.2)55 (71.4) |
| Cost of the vaccine Effectiveness of the vaccine |
20 (26.0)19 (24.7) | 57 (74.0)58 (75.3) |
| Description of the dosage | 17 (22.1) | 60 (77.9) |
| Adverse effects of the vaccine | 16 (20.8) | 61 (79.2) |
| Recommendation in children Route of administration of the vaccine |
14 (18.2)12 (15.6) | 63 (81.8)65 (84.4) |
| Recommendation in teenagers Shortage of the vaccine Recommendation in young adults |
9 (11.7)5 (6.5)4 (5.2) | 68 (88.3)72 (93.5)73 (94.8) |
| Recommendation in cases of asplenic patients | 3 (3.9) | 74 (96.1) |
| Recommendation in cases of terminal complement pathway deficiencies | 3 (3.9) | 74 (96.1) |
| Recommendation for laboratory staff | 3 (3.9) | 74 (96.1) |
| Recommendation in cases of properdin deficiency Recommendation in cases of treatment with eculizumab Recommendation in cases of previous IMDa |
1 (1.3)1 (1.3) 0 (0) |
76 (98.7)76 (98.7) 77 (100) |
aIMD: invasive meningococcal disease.